Aim: To investigate the efficacy and safety of intravenous retosiban in women with spontaneous preterm labour.
INTRODUCTION
Preterm birth is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability [1] [2] [3] [4] . Current tocolytics may not be effective in delaying delivery for a number of possible reasons [1, [5] [6] [7] : the drug target may be inappropriate, the plasma concentration may be ineffective, or redundant mechanisms may allow the process of labour to continue. Clinicians remain optimistic that an effective tocolytic will be developed which can significantly prolong pregnancy and improve neonatal and infant outcomes in appropriate pregnancies.
Atosiban, a mixed vasopressin (V 1a )/oxytocin receptor antagonist, is licensed in the European
Union as a tocolytic for parenteral administration [8] . There are no tocolytics currently approved in North America. Many therapies are used off-label throughout the world, including beta-sympathomimetics, prostaglandin synthase inhibitors, and calcium channel blockers [9] , although none have been conclusively demonstrated to delay delivery and improve neonatal or infant outcomes. Retosiban, a specific, high-affinity oxytocin receptor antagonist, is now in development for the inhibition of uterine contractions in spontaneous preterm labour. Retosiban is an oxazole diketopiperazine oxytocin antagonist with good bioavailability and nanomolar affinity for the human oxytocin receptor (Ki=0.65 nM), with >1400-fold selectivity over the closely related vasopressin receptors [10] . Nomenclature for the vasopressin and oxytocin receptors is as specified in the Guide to Receptors and Channels (GRAC), 5th edition [11] .
There is evidence from in vitro and in vivo studies that retosiban inhibits spontaneous and GlaxoSmithKline, King of Prussia, PA, USA) and retosiban has been evaluated in pregnant women to determine the dose-range and confirm proof of mechanism based on suppression of uterine contractions [12, 13] . The pilot dose ranging studies were done on 29 women in threatened preterm labour between 34 and 35 +6 weeks' gestation. These studies (to be published separately) demonstrated rapid absorption of retosiban with plasma concentrations consistent with nonpregnant volunteers. The safety profile was similar to placebo. Retosiban was associated with a reduction in uterine activity and a marked increase in the number of days to delivery. In the current report, proof-of-concept was further extended to confirm the efficacy and safety of intravenous retosiban in women experiencing spontaneous preterm labour between 30 0/7 and 35 6/7 weeks' gestation with an uncomplicated singleton pregnancy.
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METHODS

Study Design
This was a double-blind, placebo-controlled study in women admitted with spontaneous The retosiban dosing regimen was designed to achieve a mean steady-state concentration of 75 ng/ml (informed by pre-clinical data, the dose-ranging study, and studies in non-pregnant healthy volunteers) using a loading dose of 6 mg over 5 minutes and a continuous infusion of 6 mg/hour over 48 hours. At any point after 1 hour of receiving the 6-mg/hour rate, a single dose increase was permitted in women who did not respond to treatment. In this case, the infusion rate could be increased to 12 mg/hour after an additional 6-mg loading dose. An adequate treatment response was defined as a clinically relevant reduction in the frequency of contractions without an increase in cervical dilatation. Women who did not respond to the dose increase could discontinue study medication and receive an alternative rescue tocolytic at the discretion of the investigator.
A group sequential design was used with up to three planned interim analyses (four planned cohorts of 16 women each). At each interim analysis, the study could have been stopped for success or futility based on a priori stopping rules.
Eligible Women
Eligible women were 18 to 45 years of age, had a singleton pregnancy between 30 0/7 and 35 6/7 weeks' gestation based on best available obstetric estimate, were having six or more uterine contractions per hour of at least 30 seconds' duration by external cardiotocography (CTG) with cervical dilatation ≥1 to ≤4 cm, and had intact fetal membranes.
Excluded were women with indications for delivery, such as pre-eclampsia or fetal compromise; women with contraindications to tocolysis, such as clinically apparent intrauterine infection or placental abruption; and women with comorbid conditions with the potential to complicate pregnancy and outcomes, such as hypertension, insulin-dependent diabetes, or substance abuse.
Procedure
Following confirmation of eligibility, maternal examination and investigations were done (vital signs; 12-lead electrocardiogram (ECG); biochemistry, haematology, and urinalysis).
An ultrasound was done to determine amniotic fluid index (AFI) and a CTG for fetal heart rate monitoring. These tests were not repeated if they had been done in the 6 hours before consent. Within 1 hour before dosing, the contraction rate and duration were determined, a vaginal examination was done to assess cervical dilatation, and fetal heart rate was recorded.
Dosing began at time zero. After the start of treatment, the following assessments were conducted at specified time points: maternal blood pressure, heart rate, ECG, uterine contractions, physical examination, clinical laboratory tests, AFI, and fetal heart rate. Women who discontinued study medication and their infants were followed for safety.
Study Endpoints
The primary pharmacodynamic endpoint (response rate) was the proportion of women who achieved and maintained uterine quiescence, defined as four or fewer contractions per hour and <1 cm change in cervical dilatation at hour 6. The principal efficacy endpoints were days to delivery (a tertiary endpoint) and preterm births (<37 weeks). The safety endpoints were aimed at detecting adverse drug effects based on maternal monitoring (ECG, laboratory results, vital signs, and adverse events), fetal monitoring (CTG, modified biophysical profile consisting of AFI and non-stress test, and adverse events), and neonatal observations (Apgar scores, growth parameters at birth and follow-up, gross development, and adverse events).
Follow-up
Women were discharged 6 hours after the end of the infusion or at the discretion of the investigator. Hospital records were reviewed to determine gestational age at birth; Apgar scores; and weight, length, and head circumference at birth. Infants were assessed approximately 1 month after birth. Neonatal adverse events were determined from either neonatal records or maternal reporting.
Statistical Analyses
The planned Bayesian statistical analysis declared statistical significance if the 95% credible interval (corresponding to the confidence interval) excluded 0 (for a difference) or 1 (for relative risk [RR]). Partially informative priors (probability distribution according to available data) from the dose-ranging study were used in the analyses of proportions of women achieving uterine quiescence and days to delivery. This was analogous to including data from a certain number of women from the prior study, as well as observed data from the present study, according to standard application of Bayes' theorem [14] . A non-informative prior (analogous to analysis of the observed data from the study) was used for the analysis of This article is protected by copyright. All rights reserved.
the proportion of preterm births and a sensitivity analysis (i.e. to evaluate the influence of the partially informative priors) for the endpoints of uterine quiescence and days to delivery. The planned sample size (n = 64) provided at least 86% power to detect a 40% absolute difference, or RR of 2.6, in the proportion of women achieving uterine quiescence.
The safety and analysis populations were defined as all women who received at least one dose of study drug. For the primary endpoint of uterine quiescence, women who stopped the study drug within 6 hours of time zero were recorded as non-responders. For analyses of days to delivery and proportion of preterm births, actual birth data were used.
Uterine quiescence response rates for each treatment group and the relative risks (defined as the ratio of retosiban to placebo response rates) along with 95% credible intervals were Helsinki (2008) 
RESULTS
Seventeen centres enrolled, randomised, and treated 64 women (Figure 1) . One additional subject was randomised but not dosed because of labour progression; her data are not included in this report. Six women did not complete the retosiban infusion due to lack of response (n = 2) or a decision on the part of the subject or investigator (n = 4). The principal reasons for discontinuation of the infusion in the placebo group (n = 12) were lack of response (n = 7), adverse event (n = 3), or subject or investigator decision (n = 2).
Demographic and baseline characteristics of women participating in the study are summarised in Table 1 . The groups were well matched. Patients were primarily white women in their mid-to-late twenties, and ranging in age from 18 to 41 years. There was a slight imbalance in randomisation, with fewer retosiban patients (9/30 vs. 15/34) randomised to the earlier gestational age group, although the increased rate of discontinuation of drug in the placebo group resulted in a similar number of patients completing the infusion in each study arm (22 and 20 for retosiban and placebo, respectively). A protocol amendment was introduced after the first 12 women were enrolled for stratification by gestational age to ensure future balanced randomisation. Although there is an imbalance of the number of women in the early gestational age group across treatments, analyses indicated that the effect of retosiban versus placebo was similar across gestational ages.
Pharmacodynamic and Efficacy Outcomes
Uterine Contractions
Uterine quiescence was achieved in 62% of women who received retosiban compared with 41% who received placebo. The RR was 1.53 (95% CrI: 0.98, 2.48; NS). The mean baseline contraction rates were 12.5 and 12.9/hour in the retosiban and placebo groups, respectively.
The rates at hour 6 were 3.7 and 5.3, respectively (Figure 2 ).
Intravenous infusion rates were increased in 37% (11/30) and 62% (21/34) of women assigned to retosiban and placebo, respectively. Ten women received rescue tocolysis: three (10%) in the retosiban group and seven (21%) in the placebo group. Rescue tocolytics included magnesium sulphate (n = 6), nifedipine (n = 3), fenoterol (n = 2), ritodrine (n = 1), atosiban (n = 1), and salbutamol (n = 1).
Time to Delivery and Preterm Births
The time to delivery was longer in women treated with retosiban compared with placebo (mean difference 8.2 days [95% CrI: 2.7, 13.74]; median time to delivery: 34.5 and 25 days, respectively). There were no deliveries within 7 days in the retosiban group, but six births (17.6%) in the placebo group. The time to delivery at each gestational age for women who received retosiban or placebo is shown in Figure 3 .
The proportion of preterm births in the retosiban and placebo groups was 18.7% (95% CrI:
7.4%, 33.7%) and 47.2% (95% CrI: 31.4%, 63.4%), respectively. The RR of preterm birth in women treated with retosiban was 0.38 (95% CrI: 0.15, 0.81).
Statistical Inference
Partially informative priors from the dose-ranging study (data from 14 subjects treated with retosiban IV and 5 treated with placebo IV) were included in the evaluation of uterine quiescence and time to delivery. The analyses were repeated using non-informative priors, which indicated that the use of these partially informative priors from the dose-ranging study had no impact on the statistical inferences, although there were minor changes to the point estimates and 95% CrI, as shown in Table 2 .
Safety
Maternal Assessments
Results from maternal ECGs, vital signs, and clinical laboratory assessments were comparable for both groups. There were no significant changes in maternal blood pressure with treatment; mean systolic and diastolic blood pressures following infusion of retosiban or placebo (0-48 hours) are shown in Figure 4 . Maternal adverse events and serious adverse events were generally similar across treatment groups. There were 14/30 (47%) adverse This article is protected by copyright. All rights reserved.
events and 2/30 (7%) serious adverse events reported in the retosiban group, compared with 17/34 (50%) and 2/34 (6%) in the placebo group. Adverse events are displayed in Table 3 and a summary of serious adverse events is shown in Table 4 . There was one report of postpartum haemorrhage that occurred more than 30 days after the completion of retosiban.
The event was considered not related to treatment.
Fetal Assessments
There were no significant changes in the modified biophysical profile and values were similar across all treatment groups. Fetal heart rate parameters were not significantly different in women treated with retosiban or placebo. In one woman in the placebo group, there was a fetal heart rate deceleration that resolved spontaneously. Mean fetal and maternal heart rates following maternal administration of retosiban or placebo (0-48 hours) are shown in Figure   5 .
Neonatal Assessments
Apgar scores and growth parameters were consistent with those expected for the estimated gestational age at birth and were similar across groups. Neonatal endpoints and gross developmental follow-up at approximately 1 month are summarised in Table 5A , B.
Adverse events were reported in 4/30 (13%) and 7/34 (21%) of retosiban-and placeboexposed neonates, respectively. Adverse events in newborns are summarised in Table 6 . Two of 30 (7%) neonates whose mothers received retosiban had a serious adverse event reported compared with 3/34 (9%) of placebo-exposed neonates ( Table 7) . Neonatal adverse events and serious adverse events were generally associated with preterm birth complications or had confounding risk factors.
DISCUSSION
The results of this study demonstrate that short-term treatment with retosiban significantly prolongs pregnancy and reduces the incidence of preterm birth. Few, if any, placebocontrolled studies have demonstrated an effect of this magnitude [7, 15, 16] . This is encouraging, as data on the efficacy of current tocolytics are contradictory and adverse effects have been reported in mothers or offspring [17] . To date, no tocolytic has been demonstrated effectively to delay delivery and improve outcome, although some agents, such as the beta-sympathomimetics, have been demonstrated to delay delivery [18] . This represents a dilemma, since it is known that babies born at later gestational ages have lower morbidity and mortality, yet delaying delivery has not been shown to improve outcome [9] . This article is protected by copyright. All rights reserved.
suggests that in this patient population the initiating stimulus may be discrete, self-limited, and non-recurrent.
The retosiban infusion was well tolerated, and there was no indication of a safety issue for mother, fetus, or newborn. A theoretical safety concern with retosiban is an increased risk of postpartum haemorrhage if delivery occurs within a few hours of infusion. A case of postpartum haemorrhage occurred more than 30 days after retosiban and was not considered related to treatment. Because of the mechanism of action of retosiban and the role of oxytocin in promoting haemostasis after delivery, it will be important to monitor similar events in subsequent trials.
Treatment discontinuations and dose escalations provide evidence that the initial retosiban dosing regimen, consisting of a 6-mg loading dose and 6-mg/hour infusion, is the lowest effective dose. More women discontinued study drug in the placebo group than in the retosiban group. In addition, more women taking placebo had their infusion rates increased compared with women taking retosiban (65% vs. 37%). As almost 40% of women on retosiban required a dose increase, it is unlikely that a dose lower than 6 mg/hour would provide adequate effect. Taken together, the data from this study support the initial 6-mg/hour infusion rate as the lowest effective dose for the majority of women, while recognising that a considerable number of women may require higher doses to attain a satisfactory response.
Strengths and Limitations
The strength of this study is that it provides evidence for the efficacy, safety, and tolerability of a specific oxytocin receptor antagonist for the treatment of spontaneous preterm labour, This article is protected by copyright. All rights reserved.
and thus represents a proof-of-concept study in this population. It is perhaps surprising that the effects on time to delivery, preterm birth, and use of rescue tocolysis were so marked,
given the heterogeneous population typical of such studies. The difference in the effect on uterine quiescence between active treatment and placebo groups was not statistically significant, although there was a markedly higher rate of quiescence in women who received retosiban (62% vs. 41%). A potential limitation of this study is that it was not, nor was it intended to be, a definitive trial to demonstrate the effectiveness of retosiban in clinical practice. Nor was it designed to demonstrate improved neonatal morbidity and mortality;
there was no long-term neonatal follow-up. The inclusion criteria, similar to many prior trials investigating tocolytic agents, did not include fetal fibronectin or cervical ultrasound, which may be used in clinical practice. Furthermore, women at early gestational ages (<30 weeks)
were not recruited.
The advent of a therapeutic intervention that could significantly prolong pregnancy in patients with spontaneous preterm labour would be invaluable. While the mode of action of retosiban in preterm labour is not fully understood, this placebo-controlled study found that the short-term administration of retosiban halted preterm labour and prolonged pregnancy to a degree that could have a positive impact on perinatal outcomes.
CONCLUSION
In conclusion, this phase 2 study provides proof-of-concept evidence for the efficacy and safety of retosiban, a prerequisite for investment in phase 3 clinical trials. Whether the tocolytic effect of retosiban results in improved neonatal and infant outcomes following preterm labour at early and late gestational ages remains to be determined.
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Prior tocolytic, n (%) 6 (20) 10 (29) BMI, body mass index; SD, standard deviation.
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